Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Medulloblastoma 1Ependymoma 1

Interventions

Radiotherapy 58Temozolomide 37Vincristine 33Cyclophosphamide 31Etoposide 25Carboplatin 25Filgrastim 23Cisplatin 22Granulocyte Colony-Stimulating Factor 18Lomustine 14Doxorubicin 13Chemotherapy, Adjuvant 13Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Topotecan 11Radiation 11Isotretinoin 11Platinum 10sargramostim 9Specimen Handling 9Radiotherapy, Conformal 9Irinotecan 9Carmustine 91,2-diaminocyclohexaneplatinum II citrate 9etoposide phosphate 8Thiotepa 8Radiotherapy, Intensity-Modulated 8Radiosurgery 8Melphalan 8Immunohistochemistry 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × omburtamab I-131 × CNS × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡